Finally, pharmacogenomic screening identified potential small molecule drugs capable of targeting breast cancer cells with elevated MiCU1/2 expression effectively, opening up avenues for personalized therapeutic interventions targeting mitochondrial calcium regulation. Here, MICU1 is linked to breast carcinoma.